Partial
Mostly Aligned
Patient Risk:
Low
Summary
Overall partial alignment: core label statements (indication, key adverse effects, and some population considerations) are supported, but there are multiple omissions and several statements not clearly supported by the FDA label. Specific dosing guidance, explicit frequency/percentages, and several management recommendations are not consistently backed by the provided label content.
Category Scores
Accurate Statements
Levothyroxine can cause heart palpitations.
6 ADVERSE REACTIONS
Levothyroxine is synthetic thyroid hormone (T4).
12.1 Mechanism of Action; 11 DESCRIPTION
Excess levothyroxine leads to temporary hyperthyroidism-like effects such as increased heart rate or irregular beats.
6 ADVERSE REACTIONS; 5 WARNINGS AND PRECAUTIONS
Excess levels raise heart rate.
6 ADVERSE REACTIONS
Overtreatment mimics hyperthyroidism.
6 ADVERSE REACTIONS
Palpitations are listed as a common side effect in levothyroxine prescribing information, affecting more than 1% of users.
6 ADVERSE REACTIONS
Pregnant women or post-thyroidectomy patients need closer TSH checks to avoid this.
8 USE IN SPECIFIC POPULATIONS - Pregnancy
T4 has a 7-day half-life.
12 CLINICAL PHARMACOLOGY; PHARMACOKINETICS
Levothyroxine replaces deficient thyroid hormone in hypothyroidism.
1 INDICATIONS AND USAGE
Unsupported Statements
Excess levels speed up metabolism.
Label does not explicitly state that excess levothyroxine speeds metabolism.
Desiccated thyroid extracts can cause more palpitations due to variable T3 spikes.
Label does not provide this comparison as a statement about desiccated thyroid relative to levothyroxine.
A 25 mcg increase correlated with transient arrhythmias in sensitive patients.
No dose-specific correlation presented in the labeled content provided.
Monitoring includes ECG if palpitations persist.
ECG monitoring for palpitations is not a universally required label statement in the provided sections.
Beta-blockers like propranolol can provide quick relief.
Label does not specify beta-blockers as a recommended or endorsed intervention.
Older adults: guidelines recommend starting at 25-50 mcg daily.
Starting-dose guidance for elderly commonly exists in labels, but the exact 25-50 mcg range is not clearly stated in the provided sections.
Heart disease patients: Those with atrial fibrillation or coronary issues face higher arrhythmia risk.
Label discusses cardiovascular warnings but does not universally quantify risk by these specific subgroups in the provided content.
Rapid up-dosing: Symptoms peak 4-6 weeks after changes.
No explicit timing window for symptom peak is presented in the provided label content.
Synthetic levothyroxine has a steady release.
Label does not state 'steady release' as a defining pharmacokinetic property.
Palpitations from overdose typically fade within 1-4 weeks after dose reduction.
No timeframe for resolution after dose change is provided in the label content.
Contradictions
Important Omissions
No explicit, label-supported dose-down titration guidance with numeric steps (e.g., 12.5-25 mcg) identified in the provided sections.
Importance:
Moderate
No explicit frequency percentages for palpitations beyond generic terms; no exact thresholds (e.g., >1%, >5%, etc.) specified in the given sections.
Importance:
Moderate
Detailed monitoring recommendations (e.g., ECG, serial TSH/FT4 measurements cadence) beyond general monitoring are not consistently enumerated.
Importance:
Moderate
Explicit statements about abrupt discontinuation avoidance are not clearly present in the provided label content.
Importance:
Moderate
Direct, explicit guidance on drug interactions with common agents (from Tables 2–5) is not summarized in the claims evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Risks described (palpitations, tachycardia, arrhythmias) are recognized adverse effects; label-supported warnings exist. Several practical dosing and monitoring specifics are not exhaustively captured in the claims and thus pose moderate safety considerations for comprehensive reporting.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not fully supported or are only partially supported by the label. Some dosing, timing, and management details are not explicitly stated in the provided label content and should be aligned to exact label language.
Suggested Improvement
Align all claims to FDA-labeled statements; remove unsupported assertions; cite exact sections for each supported claim; provide precise dosing/titration guidance and monitoring recommendations as stated in the label.